INTARCIA THERAPEUTICS, INC
implantable drug delivery system for continuous therapeutic release
- Sector
- Medtech
- Headquarters
- Boston, MA
- Latest Form D
- $73.1M, Mar 2019
- Total capital
- $656M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $656M
- 11 Form D · last Mar 2019
- 92 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 28
- 12 pending · first 2017
- Rank in peer group#56 of 1112
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 11th filing$73.1M
- Private capital raisedForm D · SEC · 10th filing$4K
- Private capital raisedForm D · SEC · 9th filing$184M
- Private capital raisedForm D · SEC · 8th filing$200M
- Private capital raisedForm D · SEC · 7th filing$699K
- Private capital raisedForm D · SEC · 6th filing$156M
- Private capital raisedForm D · SEC · 5th filing$7.9M
- Private capital raisedForm D · SEC · 4th filing$7.3M
- Private capital raisedForm D · SEC · 3rd filing$5M
- Private capital raisedForm D · SEC · 2nd filing$14.5M
- Private capital raisedForm D · SEC · 1st filing$7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1112 peers
Line = medianMedtech · Device
- Granted patents#56 · top 5%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Thomas J. AlessiResearcherExecutive OfficerLinked by 4 patents
- Jay SmithResearcherExecutive OfficerLinked by 3 patents
- Anders VintherExecutive OfficerNamed in SEC Form D filings
- Anthony HurleyExecutive OfficerNamed in SEC Form D filings
- Barbara L. McClungExecutive OfficerNamed in SEC Form D filings
- Bob KerreyDirectorNamed in SEC Form D filings
Show all 33 people
- Bryan RobertsDirectorNamed in SEC Form D filings
- David FranklinExecutive OfficerNamed in SEC Form D filings
- David SpellmanExecutive OfficerNamed in SEC Form D filings
- Ed R. MathersDirectorNamed in SEC Form D filings
- Emad RizkDirectorNamed in SEC Form D filings
- Fred FiedorekExecutive OfficerNamed in SEC Form D filings
- Gino SantiniDirectorNamed in SEC Form D filings
- Glen SatoDirectorNamed in SEC Form D filings
- Irwin ScherDirectorNamed in SEC Form D filings
- James AhlersExecutive OfficerNamed in SEC Form D filings
- James R. NiedelDirectorNamed in SEC Form D filings
- Jay SkylerDirectorNamed in SEC Form D filings
- Jim RosenthalDirectorNamed in SEC Form D filings
- John YeeExecutive OfficerNamed in SEC Form D filings
- Kenneth L. LuskeyExecutive OfficerNamed in SEC Form D filings
- K. Alice LeungExecutive Officer, DirectorNamed in SEC Form D filings
- Kurt GravesExecutive Officer, DirectorNamed in SEC Form D filings
- Michael WilliamsExecutive OfficerNamed in SEC Form D filings
- Michelle J. BaronExecutive OfficerNamed in SEC Form D filings
- Nancy ThornberryDirectorNamed in SEC Form D filings
- Owen Hughes, Jr.Executive OfficerNamed in SEC Form D filings
- Patrick ConwayDirectorNamed in SEC Form D filings
- Paul FeldmanExecutive OfficerNamed in SEC Form D filings
- Raymond KeaneExecutive OfficerNamed in SEC Form D filings
- Sunita ZalaniExecutive OfficerNamed in SEC Form D filings
- Thane WettigExecutive OfficerNamed in SEC Form D filings
- Tom G. AlessiExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 28 granted of 40- GrantedLong Acting Peptide Tyrosine Tyrosine (pyy) Analogs And Methods Of UseUSPTOUS 12,122,816
- GrantedLong Acting Glucagon Like POLYPEPTIDE-1 (GLP-1) Receptor Agonists And Methods Of UseUSPTOUS 12,084,485
- GrantedRapid Establishment And/or Termination Of Substantial Steady-state Drug DeliveryUSPTOUS 12,042,557
Show all 40 patent records
- Long Acting Peptide Tyrosine Tyrosine (pyy) Analogs And Methods Of UseOct 22, 2024 · US 12,122,816Granted
- Long Acting Glucagon Like POLYPEPTIDE-1 (GLP-1) Receptor Agonists And Methods Of UseSep 10, 2024 · US 12,084,485Granted
- Rapid Establishment And/or Termination Of Substantial Steady-state Drug DeliveryJul 23, 2024 · US 12,042,557Granted
- Human Amylin Analog Polypeptides And Methods Of UseJun 25, 2024 · US 12,018,059Granted
- Glucagon-receptor Selective Polypeptides And Methods Of Use ThereofDec 12, 2023 · US 11,840,559Granted
- Long Acting Peptide Tyrosine Tyrosine (pyy) Analogs And Methods Of UseAug 29, 2023 · US 11,739,134Granted
- Methods Comprising Continuous Administration Of Exenatide And Co-administration Of A DrugMay 23, 2023 · US 11,654,183Granted
- Implant Placement GuideAug 30, 2022 · US D,962,433Granted
- Suspension formulation comprising an insulinotropic peptideFeb 15, 2022 · US 11,246,913Granted
- Glucagon-receptor Selective Polypeptides And Methods Of Use ThereofJan 4, 2022 · US 11,214,607Granted
- Implant Removal Tool And AssemblyOct 12, 2021 · US D,933,219Granted
- Implant Placement And Removal SystemsOct 7, 2021 · Application 17121576Pending
- Implant Removal ToolMar 2, 2021 · US D,912,249Granted
- Implant Placement And Removal SystemsFeb 23, 2021 · US 10,925,639Granted
- THERAPEUTIC METHODS FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS FOR PATIENTS WITH HIGH BASELINE HbA1cDec 24, 2020 · Application 16750432Pending
- Rapid Establishment And/or Termination Of Substantial Steady-state Drug DeliveryDec 22, 2020 · US 10,869,830Granted
- THERAPEUTIC METHODS FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS FOR PATIENTS WITH HIGH BASELINE HbA1cNov 19, 2020 · Application 16984435Pending
- Methods Comprising Continuous Administration of a GLP-1 Receptor Agonist and Co-administration of a DrugNov 17, 2020 · US 10,835,580Granted
- Apparatus And Methods For Administration Of A Nauseogenic Compound From A Drug Delivery DeviceJun 18, 2020 · Application 16491275Pending
- THERAPEUTIC METHODS FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS FOR PATIENTS WITH HIGH BASELINE HbA1cMar 10, 2020 · US 10,583,080Granted
- Osmotic Delivery Systems And Piston Assemblies For Use ThereinJan 7, 2020 · US 10,527,170Granted
- Glucagon-receptor Selective Polypeptides And Methods Of Use ThereofDec 10, 2019 · US 10,501,517Granted
- Devices, Formulations, And Methods For Delivery Of Multiple Beneficial AgentsOct 15, 2019 · US 10,441,528Granted
- Implant Removal ToolSep 17, 2019 · US D,860,451Granted
- Method Of Manufacturing An Osmotic Delivery DeviceJul 30, 2019 · US 10,363,287Granted
- Rapid Establishment And/or Termination Of Substantial Steady-state Drug DeliveryMar 19, 2019 · US 10,231,923Granted
- Implant Placement GuideFeb 5, 2019 · US D,840,030Granted
- Compositions, Devices And Methods Of Use Thereof For The Treatment Of CancersDec 25, 2018 · US 10,159,714Granted
- Implant Placement GuideDec 11, 2018 · US D,835,783Granted
- THERAPEUTIC METHODS FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS FOR PATIENTS WITH HIGH BASELINE HbA1cFeb 13, 2018 · US 9,889,085Granted
- Solvent/polymer Solutions As Suspension VehiclesDec 7, 2017 · Application 15626483Pending
- Stable Non-aqueous Single Phase Viscous Vehicles And Formulations Utilizing Such VehiclesNov 9, 2017 · Application 15658046Pending
- Methods Of Manufacturing Viscous Liquid Pharmaceutical FormulationsNov 9, 2017 · Application 15658965Pending
- Two-piece, Internal-channel Osmotic Delivery System Flow ModulatorJun 29, 2017 · Application 15347261Pending
- Osmotic Delivery Device Comprising An Insulinotropic Peptide And Uses ThereofJun 20, 2017 · US 9,682,127Granted
- Stable Non-aqueous Single Phase Viscous Vehicles And Formulations Utilizing Such VehiclesMay 4, 2017 · Application 15408344Pending
- Highly Concentrated Drug Particles, Formulations, Suspensions And Uses ThereofMay 4, 2017 · Application 15408112Pending
- Devices, Formulations, And Methods For Delivery Of Multiple Beneficial AgentsMar 23, 2017 · Application 15362240Pending
- Solvent/polymer Solutions As Suspension VehiclesMar 2, 2017 · Application 15340882Pending
- Devices, Formulations, And Methods For Delivery Of Multiple Beneficial AgentsFeb 21, 2017 · US 9,572,889Granted
Related companies, and why
- SOLIX Algredients, INC.Similar federal contract value in Medtech · null in contracts
- EPINEX DIAGNOSTICS INCSimilar federal contract value in Medtech · null in contracts
- NUVASIVE INCSimilar federal contract value in Medtech · null in contracts
- Neuros Medical, Inc.Similar federal contract value in Medtech · null in contracts
- Goodman Consulting Group, LLCSimilar federal contract value in Medtech · null in contracts
- Rani Therapeutics, LLCSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .